AR074844A1 - Composiciones farmaceuticas con saponinas - Google Patents
Composiciones farmaceuticas con saponinasInfo
- Publication number
- AR074844A1 AR074844A1 ARP090105036A ARP090105036A AR074844A1 AR 074844 A1 AR074844 A1 AR 074844A1 AR P090105036 A ARP090105036 A AR P090105036A AR P090105036 A ARP090105036 A AR P090105036A AR 074844 A1 AR074844 A1 AR 074844A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- composition according
- tumor
- pharmaceutical compositions
- immunopotentiator
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 8
- 229930182490 saponin Natural products 0.000 title abstract 4
- 150000007949 saponins Chemical class 0.000 title abstract 4
- 235000017709 saponins Nutrition 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 230000006378 damage Effects 0.000 abstract 3
- 230000000091 immunopotentiator Effects 0.000 abstract 3
- 230000003308 immunostimulating effect Effects 0.000 abstract 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229960001438 immunostimulant agent Drugs 0.000 abstract 2
- 239000003022 immunostimulating agent Substances 0.000 abstract 2
- 238000011065 in-situ storage Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 241001644525 Nastus productus Species 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La presente se refiere a composiciones farmacéuticas para usar en la terapia de destrucción del tumor in situ, que comprende los pasos de destruir el tumor y administrar una cantidad inmunoestimulante de un inmunopotenciador, y al uso de dichas composiciones farmacéuticas en la fabricación de un medicamento. Reivindicación 1: Una composición farmacéutica para usar en la terapia de destrucción del tumor in situ, que comprende los pasos de destruir el tumor y administrar una cantidad inmunoestimulante de un inmunopotenciador, caracterizada porque dicho inmunopotenciador es una saponina. Reivindicación 2: Una composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque dicha saponina comprende al menos uno de los siguientes componentes: QS-7, QS-17, QS-18, QS-21, QuilA, Vax Sap, SuperSap, GPI-0100 ó QP de 1000. Reivindicación 3: Una composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque la saponina se encuentra en forma de un complejo inmunoestimulante vacío. Reivindicación 4: Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 3, caracterizada porque además, comprende un CpG ODN. Reivindicación 11: El uso de una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 4, en la fabricación de un medicamento para el tratamiento de un mamífero que sufre de cáncer, en el cual el mamífero se ha sometido a la destrucción del tumor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08172775 | 2008-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074844A1 true AR074844A1 (es) | 2011-02-16 |
Family
ID=42103006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090105036A AR074844A1 (es) | 2008-12-23 | 2009-12-22 | Composiciones farmaceuticas con saponinas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110256167A1 (es) |
| EP (1) | EP2381949B1 (es) |
| JP (1) | JP5527908B2 (es) |
| CN (1) | CN102264373B (es) |
| AR (1) | AR074844A1 (es) |
| AU (1) | AU2009331531B2 (es) |
| BR (1) | BRPI0923598A2 (es) |
| CA (1) | CA2747938C (es) |
| ES (1) | ES2399218T3 (es) |
| TW (1) | TWI389694B (es) |
| WO (1) | WO2010072743A1 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113271970A (zh) * | 2018-09-27 | 2021-08-17 | 健诺西生物科学公司 | 治疗方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077638B (zh) * | 2022-12-20 | 2024-03-26 | 国药中生生物技术研究院有限公司 | 一种复合佐剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149527A (en) * | 1990-09-18 | 1992-09-22 | Oncotech, Inc. | Immunopotentiating protocol for chemotherapy-responsive tumors |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6316007B1 (en) * | 1995-04-04 | 2001-11-13 | Wound Healing Of Oklahoma | Combined physical and immunotherapy for cancer |
| US20010034330A1 (en) * | 1998-08-10 | 2001-10-25 | Charlotte Kensil | Innate immunity-stimulating compositions of CpG and saponin and methods thereof |
| DK1104306T3 (da) * | 1998-08-10 | 2006-05-22 | Antigenics Inc | Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf |
| GB0323968D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
| US20050175623A1 (en) * | 2004-02-10 | 2005-08-11 | Zheng-Pin Wang | Saponins as anticancer agent |
| AU2007322424B2 (en) | 2006-11-20 | 2013-05-16 | Duecom | Use of lipid containing particles comprising quillaja saponins for the treatment of cancer |
-
2009
- 2009-12-22 CA CA2747938A patent/CA2747938C/en not_active Expired - Fee Related
- 2009-12-22 ES ES09798927T patent/ES2399218T3/es active Active
- 2009-12-22 TW TW098144222A patent/TWI389694B/zh not_active IP Right Cessation
- 2009-12-22 BR BRPI0923598A patent/BRPI0923598A2/pt not_active Application Discontinuation
- 2009-12-22 US US13/141,157 patent/US20110256167A1/en not_active Abandoned
- 2009-12-22 CN CN200980151731.3A patent/CN102264373B/zh not_active Expired - Fee Related
- 2009-12-22 JP JP2011542808A patent/JP5527908B2/ja not_active Expired - Fee Related
- 2009-12-22 AR ARP090105036A patent/AR074844A1/es not_active Application Discontinuation
- 2009-12-22 WO PCT/EP2009/067721 patent/WO2010072743A1/en active Application Filing
- 2009-12-22 EP EP09798927A patent/EP2381949B1/en not_active Not-in-force
- 2009-12-22 AU AU2009331531A patent/AU2009331531B2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113271970A (zh) * | 2018-09-27 | 2021-08-17 | 健诺西生物科学公司 | 治疗方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2381949B1 (en) | 2012-11-21 |
| JP2012513444A (ja) | 2012-06-14 |
| CN102264373A (zh) | 2011-11-30 |
| US20110256167A1 (en) | 2011-10-20 |
| WO2010072743A1 (en) | 2010-07-01 |
| EP2381949A1 (en) | 2011-11-02 |
| AU2009331531A1 (en) | 2010-07-01 |
| JP5527908B2 (ja) | 2014-06-25 |
| ES2399218T3 (es) | 2013-03-26 |
| TWI389694B (zh) | 2013-03-21 |
| TW201034676A (en) | 2010-10-01 |
| CN102264373B (zh) | 2014-05-14 |
| BRPI0923598A2 (pt) | 2016-01-26 |
| AU2009331531B2 (en) | 2013-06-13 |
| CA2747938C (en) | 2018-06-05 |
| CA2747938A1 (en) | 2010-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2532850T3 (es) | Uso terapéutico de al menos una neurotoxina botulínica en el tratamiento del dolor inducido por al menos un agente anticanceroso | |
| AR107285A2 (es) | Vacuna | |
| CU20070203A7 (es) | Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer | |
| BR112019000598A2 (pt) | rna para terapia de câncer | |
| CO2017007959A2 (es) | Composiciones farmacéuticas para terapia combinada | |
| CR20170424A (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb | |
| CL2016000650A1 (es) | Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento. | |
| UY33700A (es) | ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?. | |
| CO6670567A2 (es) | Métodos de tratamiento contra el cáncer pancreático | |
| AR095962A1 (es) | Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos | |
| CL2012000248A1 (es) | Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina. | |
| ECSP13012534A (es) | Composición farmacéutica | |
| UY32989A (es) | Coposiciones terapéuticas concentradas de fosfolípidos | |
| CR20170456A (es) | Composiciones farmacéuticas para terapias combinadas | |
| CO6781465A2 (es) | Composición farmacéutica, métodos de tratamiento y usos de la misma | |
| CL2011002595A1 (es) | Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion. | |
| UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
| CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
| AR068565A1 (es) | Composiciones para el tratamiento del cabello | |
| CL2016002276A1 (es) | Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| AR092897A1 (es) | Composiciones inmunogenicas | |
| AR073528A1 (es) | Particulas inhalables que comprenden tiotropio | |
| AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |